WASHINGTON, April 26, 2021 / PRNewswire / – Danaher Corporation (NYSE: DHR) (“Danaher”), the global science and technology company, today announced the formation of a science advisory board (“board”) to support its innovation strategy and investment.
The board will help the company protect and develop existing scientific innovations, support its development of new technologies, and bring unique perspectives to emerging science and technology trends impacting Danaher.
The Council is made up of eminent scientists, including two Nobel Laureates, with global experience and research expertise in all areas of the health sciences. The board will work with Danaher’s management team and its board of directors to assess merger and acquisition opportunities and to prioritize start-up investments in strategic areas. They will also be responsible for collaborating with Danaher’s own scientific community to create proprietary knowledge and develop promising innovations to support clients.
Rainer Blair, President Danaher & CEO, said: “An important part of Danaher’s competitive advantage and key to our long-term success is the innovative expertise we bring to meet the world’s most pressing health and safety needs. of our customers. Scientists who have generously agreed to join our Scientific Council will play an inspiring role, working closely with our own teams to challenge, validate and guide our scientific agenda – aligning our priorities with the ever-changing needs of our clients and the world. world. ”
“We are at a critical inflection point in accelerating science and technology,” added JC Gutiérrez-Ramos, Scientific Director of Danaher. “We are witnessing the convergence of scientific disciplines that are accelerating the opportunities to affect human health on a large scale, expand access to health care, reduce suffering and improve health status in the world. world. us to imagine and shape that future. ”
The members of Danaher’s scientific council are:
- Angela Caliendo, MD, Ph.D. Warren Alpert Foundation Professor of Medicine and Executive Vice President of Medicine at Alpert Medical School of Brown University; and President of Brown Physicians, Inc. A specialist in molecular infectious diseases with a global reputation.
- James j collins, Ph.D. Termeer Professor of Bioengineering at the Department of Biological Engineering and at the Institute of Medical Engineering and Sciences. Leader in synthetic biology and systems biology, with a focus on the application of network biology approaches to study antibiotic action, bacterial defense mechanisms and antibiotic resistance.
- Robert Hershberg, MD, Ph.D. Venture Partner at Frazier Healthcare Partners. Expert in the fields of immuno-oncology and translational medicine, passionate about the advancement of early cancer detection technologies.
- Isaac S. Kohane, MD, Ph.D. Marion V. Nelson Professor of Biomedical Informatics, Harvard School of Medicine; Director of the Biomedical Informatics Department, Harvard School of Medicine; and Associate Professor of Medicine, Brigham and Women’s Hospital. Expert in applying data – including AI – to derive new diagnoses and deliver the best available care faster.
- Amy lynn mcguire, JD, Ph.D. Leon Jaworski Professor of Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy at Baylor College of Medicine. Expert in clinical integration of emerging technologies, with a focus on ethical and policy issues in human genetics and genomics research.
- David rimm, MD, Ph.D. Professor of Pathology and Medicine, Director of Tissue Pathology Services and Director of Translational Pathology, Yale School of Medicine. Specializes in immuno-oncology, molecular pathology methods, including NGS, and has extensive experience in AI-based image analysis in pathology.
- Phillip a sharp, Ph.D. & Nobel Laureate Institute professor and professor of biology, MIT, and member of the Koch Institute for Integrative Cancer Research. Pioneer in the molecular biology of the mechanisms of RNA splicing and its implication in cancer.
- Thomas C. Südhof, MD and Nobel Laureate Avram Goldstein Research Professor, Howard Hughes Medical Institute; Professor, Department of Molecular and Cellular Physiology and Neurosurgery, Professor (by courtesy), Department of Neurology and Neurological Sciences and Psychiatry and Behavioral Sciences, Stanford Medicine. Pioneer in the study of the functioning of synapses, including the molecular basis of neuroscience and brain chemistry.
- David R. Walt, Ph.D. Professor Hansjörg Wyss of Biologically Inspired Engineering, Harvard School of Medicine; Professor of Pathology at Brigham and Women’s Hospital; Main faculty of the Wyss Institute in Harvard University; and professor at the Howard Hughes Institute of Medicine. Founder of Illumina and Quanterix. Pioneer in the use of microwells for DNA, RNA and protein analysis, which revolutionized the field.
For more information on the Scientific Council, visit: https://www.danaher.com/who-we-are/leadership-team.
Danaher is a global science and technology innovator committed to helping clients solve complex challenges and improve the quality of life around the world. Its world-class family of brands occupy leading positions in the demanding and attractive end markets of health, environment and applications. With more than 20 operating companies, Danaher’s diverse global team of approximately 69,000 associates is united by a common culture and operating system, the Danaher Business System and its common goal, Help realize the potential of life.
For more information on Danaher, please visit www.danaher.com.
SOURCE Danaher Corporation